Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Hoover RG, Lary C, Page R, Travis P, Owens R, Flick J, Kornbluth J, Barlogie B.

J Clin Invest. 1995 Jan;95(1):241-7.

2.

Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.

Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, et al.

Blood. 1995 Jul 1;86(1):390-7.

3.

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.

Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, Martinelli G, Cavo M, Amabile M, Mangianti S, Fogli M, Conte R, Tura S.

Blood. 1996 Feb 15;87(4):1625-34.

4.

Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody.

Jewett A, Teruel A, Romero M, Head C, Cacalano N.

Cancer Immunol Immunother. 2008 Jul;57(7):1053-66. doi: 10.1007/s00262-007-0437-6.

PMID:
18188563
6.
7.

Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.

Letessier EM, Heo DS, Okarma T, Johnson JT, Herberman RB, Whiteside TL.

Cancer Res. 1991 Aug 1;51(15):3891-9.

8.

Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.

Keler T, Wallace PK, Vitale LA, Russoniello C, Sundarapandiyan K, Graziano RF, Deo YM.

J Immunol. 2000 Jun 1;164(11):5746-52.

9.

Phenotypic and functional characterization of cytotoxic cells derived from endomyocardial biopsies in human cardiac allografts.

Trentin L, Zambello R, Faggian G, Livi U, Thiene G, Gasparotto G, Agostini C.

Cell Immunol. 1992 May;141(2):332-41.

PMID:
1374288
10.

Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.

Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B.

Br J Haematol. 1991 Nov;79(3):421-7.

PMID:
1721526
11.

Increased expression of Fc gamma receptor in cancer patients and tumor bearing mice.

Ran M, Teillaud JL, Fridman WH, Frenkel H, Halachmi E, Katz B, Gips M, Shlomo Y, Barzilay J, Witz IP.

Mol Immunol. 1988 Nov;25(11):1159-67.

PMID:
2851735
12.

A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function.

Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, Pantaleo G, Moretta L.

J Exp Med. 1990 Mar 1;171(3):695-714.

13.

Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.

Kay NE, Oken MM, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P.

Leuk Lymphoma. 1995 Jan;16(3-4):351-4.

PMID:
7719242
14.

In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.

Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM.

Blood. 1995 Jan 15;85(2):436-47. Erratum in: Blood 1995 Jun 1;85(11):3365.

15.

CD16- CD56+ natural killer cells after bone marrow transplantation.

Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE.

Blood. 1992 Jun 15;79(12):3239-44.

16.
17.
18.

Growth inhibition of RPMI 8226 human myeloma cells by peripheral blood lymphocytes.

Amano T, Katagiri S, Tominaga N, Oritani K, Tamaki T, Kanayama Y, Yonezawa T, Tarui S.

Acta Haematol. 1992;87(1-2):37-44.

PMID:
1350158
19.

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.

García-Sanz R, González M, Orfão A, Moro MJ, Hernández JM, Borrego D, Carnero M, Casanova F, Bárez A, Jiménez R, Portero JA, San Miguel JF.

Br J Haematol. 1996 Apr;93(1):81-8.

PMID:
8611480
20.

Supplemental Content

Support Center